Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors GlobeNewswire - Wed Nov 19, 2025

BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

NERV : 4.02 (-0.99%)
Minerva Neurosciences: Q3 Earnings Snapshot AP - Wed Nov 5, 2025

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 4.02 (-0.99%)
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates GlobeNewswire - Wed Nov 5, 2025

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

NERV : 4.02 (-0.99%)
Minerva Neurosciences: Q2 Earnings Snapshot AP - Thu Aug 14, 2025

Minerva Neurosciences: Q2 Earnings Snapshot

NERV : 4.02 (-0.99%)
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results GlobeNewswire - Thu Aug 14, 2025

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025...

NERV : 4.02 (-0.99%)
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates GlobeNewswire - Tue May 13, 2025

NERV : 4.02 (-0.99%)
Minerva Neurosciences: Q1 Earnings Snapshot AP - Tue May 13, 2025

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 4.02 (-0.99%)
Minerva Neurosciences: Q4 Earnings Snapshot AP - Tue Feb 25, 2025

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 4.02 (-0.99%)
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates GlobeNewswire - Tue Feb 25, 2025

NERV : 4.02 (-0.99%)
Minerva Neurosciences: Q3 Earnings Snapshot AP - Tue Nov 5, 2024

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 4.02 (-0.99%)

Barchart Exclusives

FTAI Aviation Is Getting into the Data Center Game. Should You Buy FTAI Stock Here? Barchart - Thu Jan 1, 3:55PM CST
FTAI Aviation has expanded beyond aviation by targeting the power needs of data infrastructure. Does this shift support buying FTAI shares? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot